Search results
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
Zacks· 6 days agoFree Report) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives ...
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
Investor's Business Daily· 5 days agoAccording to data collected by Iqvia, the number of prescriptions of Novartis' (NVS) Hyrimoz has...
AbbVie's Upadacitinib shows promise in giant cell arteritis study By Investing.com
Investing.com· 6 days agoThe study met both its primary endpoint and key secondary endpoints, with a higher percentage of...
Abbvie Inc [ABBV] Shares Rise 1.05 % on Wednesday – Knox Daily
Knox Daily· 7 days agoInvestors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Abbvie Inc shares valued at $3,716,757 were sold by Donoghoe ...
Fake Botox injections have sickened 22, hospitalized 11, CDC warns
LiveScience· 1 day agoIn recent months, 22 people across 11 U.S. states have developed symptoms like blurry vision and...
CDC issues health advisory about risks of counterfeit or mishandled Botox injections
KETV 7 Omaha· 20 hours agoThe U.S. Centers for Disease Control and Prevention issued an advisory Tuesday about the risks of...
EU regulators approve Pfizer antibiotic Emblaveo (NYSE:PFE)
Seeking Alpha· 2 days agoEU regulators have approved Pfizer (PFE) and AbbVie’s (ABBV) antibiotic product Emblaveo for the...
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
The Wall Street Journal· 6 days agoAbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. But the latest results from Cerevel’s Parkinson’s disease late-stage trial just made the ...
CDC issues health advisory warning of 'adverse effects' from fake Botox injections
Fox News· 9 hours agoThe U.S. Centers for Disease Control and Prevention (CDC) issued an official health alert advisory...
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
Morningstar· 6 days agoBy Denny Jacob AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease. The drugmaker said ...